Leukeran (Chlorambucil)

Leukeran (chlorambucil) is employed as an oral alkylating antineoplastic agent in the treatment of several indolent lymphoid cancers, acting to suppress malignant cell proliferation.

• Chronic lymphocytic leukemia: provides disease control and prolongs survival in adult patients.
• Hairy cell leukemia: induces remission by targeting malignant B‑cells.
• Low‑grade non‑Hodgkin lymphoma: contributes to tumor reduction when used in combination therapy.
• Waldenström macroglobulinemia: offers therapeutic benefit in selected cases.
• Chronic myelogenous leukemia (blast phase): may be used as part of combination regimens to reduce leukemic burden.

• Chlorambucil exerts its antineoplastic activity by alkylating nucleophilic sites on DNA, primarily the N7 position of guanine residues. This alkylation creates intra‑ and interstrand cross‑links that impede DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing lymphoid cells. The drug is absorbed orally and undergoes hepatic metabolism to active metabolites that retain DNA‑binding capacity. The resulting DNA damage activates cellular checkpoints and leads to programmed cell death.

Chlorambucil may cause a range of adverse reactions, varying from mild to severe, that require monitoring during therapy.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Fatigue: persistent tiredness.
• Low blood cell counts: anemia, neutropenia, thrombocytopenia.
• Alopecia: hair thinning or loss.

Serious or Rare Side Effects

• Bone marrow aplasia: severe suppression of blood cell production.
• Secondary malignancies: increased risk of therapy‑related cancers.
• Severe allergic reactions: rash, angioedema, anaphylaxis.

When prescribing or handling Leukeran, several precautionary measures should be observed to minimize risks and ensure patient safety.

• Baseline assessment: obtain complete blood count and liver function tests before initiating therapy.
• Monitoring: perform regular hematologic evaluations to detect cytopenias early.
• Infection risk: advise patients to report fever or signs of infection promptly.
• Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks.
• Storage: Store below 25°C: keep in original container, protect from moisture and light.

Chlorambucil can interact with other medicines, altering its efficacy or increasing toxicity; awareness of these interactions guides safe co‑administration.

Major Interactions (Avoid)

• Live vaccines: may cause uncontrolled infection due to immunosuppression.
• Strong CYP2C9 inhibitors (e.g., fluconazole): increase chlorambucil plasma levels, raising toxicity risk.
• Myelosuppressive agents (e.g., cyclophosphamide): additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): enhanced bleeding risk, monitor INR.
• Allopurinol: may increase risk of myelosuppression, adjust monitoring.
• NSAIDs: can exacerbate gastrointestinal irritation, advise caution.